Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa Therapy or Other Recombinant Erythropoietins

NCT00211029 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.

NCT NCT00211029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00211029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa Therapy or Other Recombinant Erythropoietins
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase
Observational
Overall status
Completed
Start date
January 31, 2003
Completion date
July 31, 2005
Enrollment
4,670 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

red-cell aplasia, pure